Royal Bank Of Canada Roivant Sciences Ltd. Transaction History

Royal Bank Of Canada

$471 Billion
Q3 2024

A detailed history of Royal Bank Of Canada transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Royal Bank Of Canada holds 31,172 shares of ROIV stock, worth $348,191. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,172

Previous 35,893 13.15%

Holding current value

$348,191

Previous $379,000 5.28%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$10.17 - $12.5 $48,012 - $59,012	-4,721 Reduced 13.15%	31,172 $359,000
Q2 2024 Aug 14, 2024	BUY	$10.36 - $11.74 $320,683 - $363,399	30,954 Added 626.73%	35,893 $379,000
Q1 2024 Nov 05, 2024	SELL	$9.87 - $11.8 $305,515 - $365,257	-30,954 Reduced 86.24%	4,939 $52,000
Q1 2024 May 15, 2024	SELL	$9.87 - $11.8 $788,751 - $942,985	-79,914 Reduced 94.18%	4,939 $52,000
Q4 2023 Feb 14, 2024	BUY	$8.38 - $11.58 $668,279 - $923,470	79,747 Added 1561.83%	84,853 $952,000
Q3 2023 Nov 14, 2023	BUY	$9.76 - $13.19 $8,744 - $11,818	896 Added 21.28%	5,106 $59,000
Q2 2023 Aug 14, 2023	BUY	$7.09 - $10.08 $28,622 - $40,692	4,037 Added 2333.53%	4,210 $42,000
Q1 2023 May 15, 2023	SELL	$6.92 - $9.98 $4,629 - $6,676	-669 Reduced 79.45%	173 $1,000
Q4 2022 Feb 14, 2023	BUY	$3.36 - $7.99 $2,829 - $6,727	842 New	842 $6,000
Q2 2022 Aug 15, 2022	SELL	$2.81 - $4.84 $17,042 - $29,354	-6,065 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.74 - $9.91 $28,700 - $60,005	6,055 Added 60550.0%	6,065 $30,000
Q4 2021 Feb 14, 2022	BUY	$5.86 - $13.52 $58 - $135	10 New	10 $0

Others Institutions Holding ROIV

# of Institutions

316

Shares Held

507M

Call Options Held

1.26M

Put Options Held

2.52M

View Full List

About Roivant Sciences Ltd.

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $7.87B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

More about ROIV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Roivant Sciences Ltd. Transaction History